Bioasis Announces Agreement With Leading Pharmaceutical Company for Pre-Clinical Research Using the xB3 Platform Technology

Under the terms of the Material Transfer Agreement, Bioasis will receive $500,000

Thank you for visiting Tailwinds Research. We are pleased to offer free research on select small and micro cap companies. However, FINRA regulations require all readers to sign onto our site. It is free to join and we hope you’ll take the time to do so.

To create an account please click on this link.

If you already have an account, please log in here.

LEAVE A REPLY